Democritus University of Thrace (DUTH)
Οι ανοσοτροποποιητικές επιδράσεις της κλαριθρομυκίνης σε ασθενείς με βρογχεκτασίες
Abstract
dc:descriptionBronchiectasis pathogenesis has been vividly illustrated as a vicious cycle of chronic infection and inflammation with mediator release. Inflammation-driven destruction of the bronchial wall and excess of mucopurulent secretions ground for further obstruction and damage of the airway and for microbial colonization responsible for recurrent infections. Th17 cells play an important role in protection against certain extracellular pathogens, by inducing a massive tissue reaction via secretion of cytokines, chemokines, metalloproteinases and antimicrobial peptides; however, they are highly pathogenic as they may promote the development or sustenance of neutrophilic inflammation and severe autoimmunity. Indeed, the neutrophilic inflammation present in cystic fibrosis and other forms of bronchiectasis is typically associated with the increased presence of Th-17 cells. Modulation of the immunologic environment of the airways with the use of anti-inflammatory drugs in patients with chronic lung inflammatory diseases has recently been the subject of growing interest. It has been previously reported that macrolide antibiotics exhibit immunomodulating activities beyond their antimicrobial action. The macrolide Clarithromycin, in particular, has been reported to modulate pro-inflammatory cytokine expression by human neutrophils, most probably due to the downregulation of transcription factors such as NF-kB, AP-1 and specificity protein-1 and that setting is exerted via inhibition of signaling of the extracellular regulated kinase ERK- 1/2 and p38 MAPK pathway. In the view of the aforementioned data and as the effect of Clarithromycin on the Th17 response in the setting of non-CF bronchiectasis has not yet been examined, this PhD thesis had three goals: a) determination of the concentrations of IL-17 in exhaled breath condensate and in serum and of circulating levels of Th17 cells in peripheral blood in patients with non-CF bronchiectasis and assessment of any potential differences in these parameters after Clarithromycin prophylactic administration, at a dose of 500 mg daily for 12 weeks, b) assessment of potential changes in lung function parameters (FEV1 and FVC after bronchodilation, PaO2 and PaCO2) and c) assessment of quality of life changes following Clarithromycin administration for 24 weeks. Clinical data regarding sputum microbiology and number of exacerbations during study period were also recorded in parallel. For this purpose, patients with clinically stable bronchiectasis, followed on a regular basis in Outpatient Clinic of the Pulmonary Department of the University Hospital of Alexanroupolis, were studied in a prospective observational manner from February 2011 to May 2012. These patients had already been considered to receive 500 mg of Clarithromycin on a daily basis. From the initial population, 22 patients fulfilled the inclusion criteria: more than 3 infective exacerbations requiring antibiotic therapy during the previous 12 months, 24-h sputum volume> 10mL and clinically stable disease. Exclusion criteria included history of smoking, asthma and atopy, regular use of inhaled corticosteroids and respiratory tract infection or exacerbation of the disease requiring therapy with antibiotics and/or systemic corticosteroids 4 weeks prior to study. Ten healthy volunteers were also studied, in order to determine the "normal" values of the examined parameters. Samples analysis resulted in significant decreases in both, post-treatment absolute counts of CD4+IL17+ cells in peripheral blood and IL-17 levels in EBC (post-treatment CD4+IL17+ mean 2.418±0.414 cells/μl versus pre-treatment 3.202±0.507 cells/μl, p=0.036 and post-treatment IL-17 mean levels 7.16±0.47 pg/ml versus pre-treatment 9.32±0.47 pg/ml, p<0.001, respectively). Post-treatment EBC IL-17 levels decreased significantly in both patients who exhibited exacerbations and those who remained stable during study period (mean 6.72±0.37 pg/ml versus 9.12±0.64 pg/ml, p=0.01 and 7.69±0.9 pg/ml versus 9.53±0.72 pg/ml, p=0.042, respectively). PaO2 improved significantly (post-treatment mean 77.73±2.23 mmHg versus pre-treatment 73.18±2.22 mmHg, p=0.025), while PaCO2, postbronchodilation FEV1 and post-bronchodilation FVC remained unaltered. Post-treatment SGRQ scores decreased significantly, totally (mean±SEM 29.93±4.32 vs 40.14±4.44 p=0.002) as well as in specific domains (symptoms, activity, impacts: 27.91±5.61 vs 38.79±4.61 p=0.036, 38.36±5.08 vs 51.34±4.88 p=0.0005 and 25.57±4.31 vs 34.28±4.89 p=0.011, respectively). SGRQ total scores decreased significantly both in non-colonized and colonized patients (mean±SEM 37.23±5.83 vs 46.74±5.39 p=0.029 and 19.38±4.73 vs 30.72±6.69 p=0.033 respectively), although significant decrease among the latter was noticed only in P.aeruginosa group (mean±SEM 31.85±9.90 vs 47.07±9.47 and 43.51±5.02 vs 46.41±5.08 respectively). Conclusively, our findings suggest that long-term, low dose Clarithromycin administration appears to reduce both local and systemic Th17 response in patients with non-CF bronchiectasis. To our knowledge the current study is the first that evaluates the influence of Clarithromycin on Th17 axis using IL-17 measurements in EBC and Th17 analysis in peripheral blood. Furthermore, our results also indicate a favorable effect in functional parameters and in quality of life, with P.aeruginosa-colonized patients probably benefitting more from the intervention
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Fouka, Evangelia
- Φούκα, Ευαγγελία
Subjects
dc:subject × 20- Βρογχεκτασίες
- Κλαριθρομυκίνη
- Μακρολίδες
- Ανοσοτροποποίηση
- Ιντερλευκίνη - 17
- Βοηθητικά Τ-17 λεμφοκύτταρα
- Συμπύκνωμα του εκπνεόμενου αέρα
- Ποιότητα ζωής
- Bronchiectasis
- Clarithromycin
- Macrolides
- Immunomodulation
- Interleukin -17
- Th-17 lymphocytes
- Exhaled breath condensate
- Quality of life
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/34931